EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitVergleichsstudie

Doxorubicin or Epirubicin Versus Liposomal Doxorubicin Therapy—Differences in Cardiotoxicity

Barbara Buchalska, Katarzyna Kamińska, Michał Kowara, Aleksandra Sobiborowicz-Sadowska, Agnieszka Cudnoch-Jędrzejewska

Cardiovascular Toxicology · 2025-02 · 25 (2) · 248-268

DOI: 10.1007/s12012-024-09952-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cardiovascular Toxicology, online erschienen am 15.01.2025. Verfasst von Barbara Buchalska und 4 weiteren Autor:innen. Beteiligte Einrichtung: Chair and Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Banacha 1b…. Hauptthemen laut MEDLINE: Doxorubicin, Antibiotics, Antineoplastic, Heart Diseases, Epirubicin. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 153 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Doxorubicin (DOX) is an important drug used in the treatment of many malignancies. Unfortunately DOX causes various side effects, with cardiotoxicity being the most characteristic. Risk factors for DOX induced cardiotoxicity (DIC) include cumulative dose of DOX, preexisting cardiovascular diseases, dyslipidemia, diabetes, smoking, along with the use of other cardiotoxic agents. Development of DIC is associated with many pathological phenomena - increased oxidative stress, as well as upregulation of ferroptosis, apoptosis, necrosis, and autophagy. In DIC expression of many microRNAs is also deregulated. In order to avoid cardiotoxicity and still use DOX effectively DOX derivatives such as epirubicin were synthesized. Nowadays a new liposomal form of DOX (L-DOX) appeared as an alternative to conventional treatment with greatly reduced cardiotoxicity. L-DOX can be divided into two groups of substances - pegylated (PLD) with increased solubility and stability, and non-pegylated (NLPD). Many metaanalyses, clinical along with preclinical studies have shown L-DOX treatment is associated with a smaller decrease of left ventricular ejection fraction (LVEF) and other heart functions, but efficacy of this treatment is comparable to the use of convenctional DOX.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinAntibiotics, AntineoplasticHeart DiseasesEpirubicinPolyethylene GlycolsCardiotoxicityHumansAnimalsVentricular Function, LeftRisk AssessmentStroke VolumeHeart Disease Risk FactorsTreatment OutcomeRisk Factors

Stichwörter der Autor:innen

Cancer treatmentCardiotoxicityDoxorubicinDoxorubicin liposomal

Substanzen

DoxorubicinAntibiotics, AntineoplasticEpirubicinliposomal doxorubicinPolyethylene Glycols

Autor:innen und Institutionen

  • Chair and Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Banacha 1b, 02-097, Warsaw, Poland.
  • Chair and Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Banacha 1b, 02-097, Warsaw, Poland. kkaminska@wum.edu.pl.

Zitieren

APA

Buchalska, B., Kamińska, K., Kowara, M., Sobiborowicz-Sadowska, A., & Cudnoch-Jędrzejewska, A. (2025). Doxorubicin or Epirubicin Versus Liposomal Doxorubicin Therapy—Differences in Cardiotoxicity. Cardiovascular Toxicology, 25(2), 248-268. https://doi.org/10.1007/s12012-024-09952-4

Vancouver

Buchalska B, Kamińska K, Kowara M, Sobiborowicz-Sadowska A, Cudnoch-Jędrzejewska A. Doxorubicin or Epirubicin Versus Liposomal Doxorubicin Therapy—Differences in Cardiotoxicity. Cardiovascular Toxicology. 2025;25(2):248-268. doi:10.1007/s12012-024-09952-4

BibTeX
@article{Buchalska2025,
  author = {Buchalska, Barbara and Kamińska, Katarzyna and Kowara, Michał and Sobiborowicz-Sadowska, Aleksandra and Cudnoch-Jędrzejewska, Agnieszka},
  title = {Doxorubicin or Epirubicin Versus Liposomal Doxorubicin Therapy—Differences in Cardiotoxicity},
  journal = {Cardiovascular Toxicology},
  year = {2025},
  volume = {25},
  number = {2},
  pages = {248--268},
  doi = {10.1007/s12012-024-09952-4}
}
Kostenlos starten →